About the Authors
- Zongchao Han, Shannon M. Conley, Rasha Makkia, Junjing Guo, Muna I. Naash
- Department of Cell Biology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States of America
- Mark J. Cooper
- Copernicus Therapeutics, Inc., Cleveland, Ohio, United States of America
MJC is an employee of Copernicus Therapeutics and owns stock and stock options in the company. There are issued and pending patents covering DNA nanoparticle compositions and their use as therapy for ocular disease. Nanoparticles are in development at Copernicus Therapeutics and there are no current marketed products. This information does not alter the authors’ adherence to all the PLOS ONE policies on sharing data and materials, as detailed online in the guide for authors.
Conceived and designed the experiments: ZH MIN. Performed the experiments: ZH SMC RM JG MIN. Analyzed the data: ZH SMC MIN. Contributed reagents/materials/analysis tools: MJC MIN. Wrote the paper: ZH SMC MJC MIN.